TRADING UPDATES: Genflow patent progress; Accsys new debt facilities
22nd Oct 2025 22:20
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
| Price | 0.11p on 14-11-2025 at 19:10:07 |
|---|---|
| Change | -0.035p -24.14% |
| Buy | 0.12p |
| Sell | 0.10p |
| Last Trade: | Buy 122,602.00 at 0.1126p |
| Day's Volume: | 65,774,340 |
| Last Close: | 0.11p |
| Open: | 0.13p |
| ISIN: | GB00BF3DT583 |
| Day's Range | 0.11p - 0.1225p |
| 52wk Range: | 0.11p - 1.65p |
| Market Capitalisation: | £1.33m |
| VWAP: | 0.113361p |
| Shares in Issue: | 1.21b |
Sector: Medical Services
Listed In: FTSE AIM All-Share,
polarean (POLX) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 122,602 | 0.1126p | Ordinary |
16:02:34 - 14-Nov-25 |
| Buy* | 2,000,000 | 0.1126p | Ordinary |
15:58:46 - 14-Nov-25 |
| Sell* | 20,000 | 0.101p | Ordinary |
15:50:33 - 14-Nov-25 |
| Sell* | 971,835 | 0.10p | Ordinary |
15:26:31 - 14-Nov-25 |
| Sell* | 2,439,888 | 0.1028p | Ordinary |
15:21:07 - 14-Nov-25 |
| Sell* | 30,000 | 0.101p | Ordinary |
15:19:29 - 14-Nov-25 |
| Sell* | 182,336 | 0.1004p | Ordinary |
15:13:25 - 14-Nov-25 |
| Sell* | 156,445 | 0.1028p | Ordinary |
15:08:22 - 14-Nov-25 |
| Buy* | 27,000 | 0.114p | Ordinary |
15:02:07 - 14-Nov-25 |
| Buy* | 201,291 | 0.114p | Ordinary |
14:59:42 - 14-Nov-25 |
polarean (POLX) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 14th Nov 2025 7:00 am | RNS | Proposed Cancellation of Admission & Notice of GM |
| 27th Oct 2025 3:37 pm | RNS | Holding(s) in Company |
| 22nd Oct 2025 7:00 am | RNS | Strategic review and consideration of AIM listing |
| 6th Oct 2025 7:00 am | RNS | Ascend Imaging agreement expansion |
| 29th Sep 2025 7:00 am | RNS | University of Virginia Health Hospital agreement |
| 25th Sep 2025 12:14 pm | RNS | National Institutes of Health system order |
| 25th Sep 2025 7:00 am | RNS | Half-year Report |
| 16th Sep 2025 7:00 am | RNS | Notice of Results |
| 11th Sep 2025 4:36 pm | RNS | Holding(s) in Company |
| 12th Aug 2025 7:00 am | RNS | Submission of new Phase III study protocol to FDA |